New Research from NetApp Finds One in Five Companies Unable to Recover Data After Cyberattack
4.12.2024 14:00:00 CET | Business Wire | Press release
Survey of cybersecurity leaders highlights the importance of data classification in enhancing cyber resilience
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced the release of its latest report analyzing the state of cybersecurity and offering actionable insights to help organizations strengthen their cyber resiliency. The Futurum Group study, "Cloud, Complexity, AI: The Triple Threat Demanding New Cyber Resilience Strategies" sponsored by NetApp, provides a comprehensive analysis of evolving cyber threats and resiliency strategies.
The study, which surveyed over 1,300 cybersecurity leaders across industries worldwide, reveals that more than 54 percent of organizations experienced a cyberattack in the past 12 to 18 months, with one in five unable to recover lost data. The report highlights the urgent need for enterprises to leverage intelligent data infrastructure to address growing risks posed by sophisticated threats, operational complexity, and the challenges of hybrid multi-cloud environments.
"The findings clearly highlight the urgency for organizations to rethink their cybersecurity strategies in an era of escalating threats,” said Gagan Gulati, General Manager for Data Services at NetApp. "To reduce risks and ensure faster recovery, businesses must adopt an intelligent data strategy that prioritizes secure-by-design infrastructures, embedding security at the core of their data management approach. With data as a company’s most valuable asset, resilient storage solutions—such as those offered by NetApp—serve as the last line of defense in a comprehensive security strategy, safeguarding critical information and enabling long-term success in hybrid multi-cloud environments."
Key Findings:
- Cloud Security Risks: Misconfigurations and vulnerabilities in hybrid multi-cloud environments are now among the top threats, outpacing traditional attacks like ransomware. As organizations rely increasingly on hybrid cloud infrastructures, addressing these vulnerabilities is critical to maintaining data security and operational continuity.
- Tool Sprawl Challenges: Seventy percent of respondents use more than 40 cybersecurity tools, with 84 percent citing operational complexity as a major inhibitor to cyber resiliency. This complexity creates protection gaps and inefficiencies, underscoring the need for tool consolidation and integrated solutions to streamline operations.
- AI in Cybersecurity: Forty percent of organizations are leveraging AI for threat detection, with plans to expand its use for automating response and recovery. AI’s ability to identify and mitigate threats at scale is powerful, but balancing its use with managing false positives and ensuring robust human oversight is essential to its success.
- Data Classification is Key: Organizations with strong data classification frameworks recover from attacks more effectively, emphasizing its role as a cornerstone of cyber resiliency. This underscores the importance of embedding intelligent data infrastructure that not only classifies and protects data but also enables real-time anomaly detection and resilient recovery, enabling business continuity even in worst-case scenarios.
- Increased Investment: Over 90 percent of respondents plan to increase cybersecurity spend in the next 12 to 18 months, focusing on integrated and proactive solutions. Proactive investment can address the rising cost of cyberattacks and the growing complexity of threats, ensuring resilience and operational trust.
NetApp's Intelligent Data Infrastructure framework helps organizations address the cyber resiliency challenges revealed in this report by enabling organizations to take a proactive approach to data protection. By leveraging advanced data classification, AI-driven threat detection, and integrated security measures, organizations can more easily implement stringent governance practices, detect and respond to threats in real-time, and maintain compliance with evolving industry standards. As highlighted by the report, organizations with resilient data infrastructure have seen significant improvements in recovery times and overall data security, demonstrating that it is a critical component in modern cybersecurity strategies.
"This survey sheds light on the critical role of visibility and data-centric strategies in navigating the evolving cybersecurity landscape," said Daniel Newman, CEO at The Futurum Group. "By harnessing intelligent data infrastructure solutions, organizations can better protect their assets, ensure recovery, and thrive amidst disruption."
The report emphasizes the critical role of AI and integrated technologies as game-changers in combating increasingly sophisticated attack vectors. By leveraging AI alongside robust data classification and consolidated toolchains, enterprises can mitigate risks more effectively, reduce response times, and enhance visibility across sprawling hybrid multi-cloud environments.
To explore the full findings of the Cybersecurity Visibility Study 2024 and discover how IT and Security leaders are thinking about challenges and opportunities shaping the future of cyber resilience in the enterprise, visit https://www.netapp.com/media/120378-netapp-cloud-complexity-ai.pdf.
Methodology
In Fall 2024, NetApp collaborated with Futurum Research to conduct a comprehensive survey of over 1,300 cybersecurity leaders worldwide. The respondents included C-Level executives, Vice Presidents, and Directors in IT and Security, representing a diverse range of industries. The report draws on insights from the survey, as well as 15 in-depth interviews with selected decision-makers, offering a detailed analysis of the challenges and opportunities shaping the cybersecurity landscape today.
Additional Resources
- Empowering Cyber Resilience in the Digital Age
- The State of Cyber Resiliency 2024/2025
- Cyber Resilience: The Most Secure Storage on the Planet
About NetApp
NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
About The Futurum Group
The Futurum Group is the fastest- growing independent tech research, intelligence, media, and advisory firm. Its organic growth is driven by emerging technologies and innovation across its clientele of more than 260 global companies. Futurum covers twelve major technology sectors: AI & data analytics, cloud, telecom, policy, consumer electronics, enterprise applications, security, semiconductors, workplace collaboration, sustainability, and CX. In 2023 it has acquired half a dozen companies in areas of research, intelligence, media, and performance testing and validation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241204675480/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom